Comment: Neuroleptic malignant syndrome versus serotonin syndrome: the search for a diagnostic tool.

suggested by the authors are of little clinical value because of the turnaroundtime associatedwith their return and challengesin interpretation. In the end, the distinction between serotonin syndrome and NMS reflectsdifferentcauses, but the treatment is the same for both.The decision as to which antidoteto initiateis of littleclinical importance,as evidence for the use of theseantidotesis sparse and conflicting.I urge medical practitioners to exercise caution in the use of dantrolene because it may in fact be harmful to patients with NMS. The evidence supporting the use of cyproheptadine in serotoninsyndromeis limitedat best.